Stock NXTC NEXTCURE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus NextCure, Inc.

Equities

NXTC

US65343E1082

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
1.35 USD +4.65% Intraday chart for NextCure, Inc. -15.62% +18.42%
04-08 NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024 CI
04-04 NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board CI

Evolution of the average Target Price on NextCure, Inc.

Price target over the last 5 years

History of analyst recommendation changes

9dea1.xDw8NikAxfpJG1-2C5WN5pKCfivUC8c-TryzcjAdulc.oW9yR1latKtwLi7hfeCgpcq2Jhu2bqtLd47xIXhQ9GWuVE4BQnSHjSNYPA~2b10dd13e53dcedfb24768a771d996ee

Analyst Recommendations on NextCure, Inc.

HC Wainwright Initiates NextCure With Buy Rating, $7 Price Target MT
BTIG Lowers NextCure's Price Target to $8 From $27, Maintains Buy Rating MT
Needham Lowers NextCure's Price Target to $6 From $12, Maintains Buy Rating MT
Roth Capital Lowers NextCure's Price Target to $4 From $6, Maintains Neutral Rating MT
Ladenburg Downgrades NextCure to Neutral From Buy MT
Piper Sandler Adjusts Price Target on NextCure to $6 From $13, Maintains Overweight Rating MT
Truist Securities Adjusts NextCure's Price Target to $15 From $19, Reiterates Buy Rating MT
Piper Sandler Lowers NextCure's Price Target to $13 From $21, Maintains Overweight Rating MT
Ladenburg Thalmann Initiates NextCure at Buy With $16 Price Target MT
Needham Adjusts Price Target on NextCure to $14 from $30, Keeps Buy Rating MT
NEXTCURE : Piper Sandler Adjusts NextCure's Price Target to $21 From $26, Maintains Overweight Rating MT
NEXTCURE : Truist Securities Upgrades NextCure to Buy From Hold; Price Target is $19 MT
NEXTCURE : BofA Securities Downgrades NextCure to Underperform From Neutral, Adjusts Price Target to $10 From $13 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.35 USD
Average target price
5 USD
Spread / Average Target
+270.37%
High Price Target
8 USD
Spread / Highest target
+492.59%
Low Price Target
3 USD
Spread / Lowest Target
+122.22%

Consensus detail

Consensus revision (last 18 months)

Analysts covering NextCure, Inc.

HC Wainwright
Piper Sandler
Ladenburg Thalmann
Roth Capital Partners
Needham & Co.
BTIG
Truist Securities
BofA Securities

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NXTC Stock
  4. Consensus NextCure, Inc.